Terlipressin

Summary

Terlipressin (CHEMBL2135460) is an approved protein (ATC H01BA04); indicated across 8 conditions including kidney failure and hepatorenal syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01BA04
• Indications: 8 conditions
• Clinical trials: 74
• Chemistry: 1227.4 Da · C52H74N16O15S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2135460
Name	Terlipressin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	72081
ATC	H01BA04
Molecular formula	C52H74N16O15S2
Molecular weight	1227.4
InChIKey	BENFXAYNYRLAIU-QSVFAHTRSA-N

SMILES: C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N

IUPAC name: (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide

Also known as: Glycylpressin, Glypressin, Terlipresina, Terlipressin, Terlipressin acetate, Terlipressine, Terlivaz, Variquel, TERLIPRESSIN, SID124896640, SID144206925, terlipressin

Parent form; salt/anhydrous children: CHEMBL4088899

Patent coverage: 2,746 distinct patent families (11,801 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Vasopressin V1a receptor, Thromboxane A2 receptor, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4D	5.01	AC50	9700	nM	CHEMBL_ACT_25185531

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
kidney failure	4	MONDO:0001106	EFO:1002048
hepatorenal syndrome	4	MONDO:0001382	MONDO:0001382
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
liver failure	2	MONDO:0100192	MONDO:0100192

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 74.

Phase distribution

Phase	Trials
Not specified	29
PHASE4	16
PHASE3	13
PHASE2	13
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00287664	PHASE4	SUSPENDED	Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
NCT00369694	PHASE4	COMPLETED	Short Course Terlipressin for Control of Acute Variceal Bleeding
NCT00534677	PHASE4	COMPLETED	The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
NCT00863837	PHASE4	UNKNOWN	Prevention of Esophageal Variceal Rebleeding
NCT00966355	PHASE4	COMPLETED	Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
NCT01530711	PHASE4	UNKNOWN	Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
NCT02059460	PHASE4	COMPLETED	Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney
NCT02119884	PHASE4	COMPLETED	Hemodynamic Effects of Terlipressin and High Dose Octreotide
NCT02489864	PHASE4	UNKNOWN	The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
NCT02757703	PHASE4	COMPLETED	Vasoactive Drugs in Real World Practice
NCT03336814	PHASE4	UNKNOWN	Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study
NCT03584087	PHASE4	COMPLETED	Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL
NCT04028323	PHASE4	UNKNOWN	Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
NCT04353193	PHASE4	UNKNOWN	Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
NCT04358016	PHASE4	COMPLETED	Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
NCT06108362	PHASE4	UNKNOWN	Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients
NCT00089570	PHASE3	COMPLETED	Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
NCT00115947	PHASE2/PHASE3	COMPLETED	Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
NCT00370253	PHASE3	COMPLETED	Noradrenalin vs Terlipressin in Hepatorenal Syndrome
NCT00628160	PHASE2/PHASE3	COMPLETED	Terlipressin in Septic Shock in Cirrhosis
NCT00986817	PHASE3	COMPLETED	Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
NCT01143246	PHASE3	COMPLETED	A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
NCT01271114	PHASE3	TERMINATED	Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension
NCT01637454	PHASE3	COMPLETED	TYPE 2 HEPATORENAL SYNDROME
NCT02770716	PHASE3	COMPLETED	Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
NCT02970175	PHASE3	COMPLETED	Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy
NCT03038503	PHASE3	UNKNOWN	What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin
NCT03822091	PHASE3	COMPLETED	Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1
NCT04460560	PHASE3	COMPLETED	Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
NCT04961528	PHASE3	COMPLETED	ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
NCT06027970	PHASE3	UNKNOWN	Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation
NCT06256432	PHASE2	ACTIVE_NOT_RECRUITING	Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
NCT00481572	PHASE2	COMPLETED	Continuous Infusion of Terlipressin in Septic Shock
NCT00793559	PHASE2	UNKNOWN	Terlipressin Administration in Septic Shock Refractory to Catecholamines
NCT01373606	PHASE1/PHASE2	COMPLETED	A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
NCT01640964	PHASE2	COMPLETED	An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
NCT01921985	PHASE2	TERMINATED	Terlipressin Administration in Patients Undergoing Major Liver Resection
NCT02368249	PHASE2	WITHDRAWN	Does Terlipressin Improve Renal Outcome After Liver Surgery
NCT02588716	PHASE2	COMPLETED	Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.
NCT02718599	PHASE2	COMPLETED	Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).